Biological
Vaccines, DNA clinical trials
Keep track of what changes. Save the Vaccines, DNA studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
9 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 7
National Institute of Allergy and Infectious Diseases (NIAID) (2) · Institut National de la Santé Et de la Recherche Médicale, France (1) · Washington University School of Medicine (1) · Nykode Therapeutics ASA (1) · National Center for AIDS/STD Control and Prevention, China CDC (1) · NEC Bio B.V (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Belarusian Research Center for Pediatric Oncology, Hematology and Immunology (1)
Often tested with
Tested in the same studies.
Rilimogene galvacirepvec (1) · Rilimogene glafolivec (1) · Nivolumab (1) · Ipilimumab (1) · RAD35 (1) · Cyclophosphamide (1) · Lenalidomide (1)
Studies
Open first, then newest update. How each study uses Vaccines, DNA is read from its arms, and is right about nine times in ten.
Testing it · 9
- Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast CancerRecruitingPhase 1/2NEC Bio B.VNCT06631092Written as Oral DNA Vaccine
- Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis BCompletedPhase 1Institut National de la Santé Et de la Recherche Médicale, FranceNCT00988767Written as DNA vaccine
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedPhase 1Washington University School of MedicineNCT03532217Written as Neoantigen DNA vaccine
- An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)CompletedPhase 1/2Nykode Therapeutics ASANCT02529930Written as VB10.16 Immunotherapy (DNA vaccine)
- DNA Vaccination Against NeuroblastomaStatus unknownEarly Phase 1Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyNCT04049864Written as DNA vaccine
- Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 VectorCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00801697Written as DNA Vaccine
- Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer PatientsTerminatedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT01493154Written as DNA Vaccine
- Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV AloneCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT01498718Written as DNA vaccine
- Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)CompletedPhase 2National Center for AIDS/STD Control and Prevention, China CDCNCT01705223Written as DNA vaccine
Given in every arm · 5 — Vaccines, DNA is usual care beside what is tested
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingPhase 2Michael K. GibsonNCT05799144Written as DNA Vaccine
- Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung CancerActive, not recruitingPhase 2Washington University School of MedicineNCT04397003Written as Neoantigen DNA vaccine
- Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care TherapyTerminatedPhase 1Washington University School of MedicineNCT03199040Written as Neoantigen DNA vaccine
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate CancerCompletedPhase 2University of Wisconsin, MadisonNCT01706458Written as DNA Vaccine
- PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell CarcinomaWithdrawnPhase 2Washington University School of MedicineNCT03598816Written as Neoantigen DNA Vaccine